Cargando…
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
The prevalence of cardiomyopathy is higher in diabetic patients than those without diabetes. Diabetic cardiomyopathy (DCM) is defined as a clinical condition of abnormal myocardial structure and performance in diabetic patients without other cardiac risk factors, such as coronary artery disease, hyp...
Autores principales: | Wang, Lin, Cai, Yin, Jian, Liguo, Cheung, Chi Wai, Zhang, Liangqing, Xia, Zhengyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783984/ https://www.ncbi.nlm.nih.gov/pubmed/33397369 http://dx.doi.org/10.1186/s12933-020-01188-0 |
Ejemplares similares
-
Carnitine regulates myocardial metabolism by Peroxisome Proliferator-Activated Receptor-α (PPARα) in alcoholic cardiomyopathy
por: Jing, Ling, et al.
Publicado: (2011) -
The importance of caveolin as a target in the prevention and treatment of diabetic cardiomyopathy
por: Xia, Weiyi, et al.
Publicado: (2022) -
Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy
por: Chung, Sungjin, et al.
Publicado: (2011) -
Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)
por: Jiang, Fang, et al.
Publicado: (2020) -
Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)